Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.

Date publication

décembre 2024

Journal

Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GRANEL-BROCARD Florence

Tous les auteurs :
Le Brun IC, Dalle S, Mortier L, Dereure O, Rat SD, Dutriaux C, Leccia MT, Legoupil D, Montaudié H, De Quatrebarbes J, Gaudy-Marqueste C, Maubec E, Saiag P, Pagès C, Possenti FB, Granel-Brocard F, Porcher R, Lefevre W, Lebbé C, Kempf E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39645590

Résumé

Nivolumab obtained approval in advanced melanoma (AM) with weight-adjusted dose (WAD) administration (3 mg/kg/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg/2 weeks or 480 mg/4 weeks) based on a modeling study, without clinical data.

Mots clés

delivery of health care, dose–response relationship, drug, health services research, immune checkpoint inhibitors, melanoma

Référence

Cancer. 2024 12 8;: